Similar articles

• Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.

  Turner PJ. Turner PJ. Diagn Microbiol Infect Dis. 2006 Nov;56(3):341-4. doi: 10.1016/j.diagmicrobio.2006.07.015. Epub 2006 Oct 17. Diagn Microbiol Infect Dis. 2006. PMID: 17049798
• [Performance evaluation of VITEK 2 system in meropenem susceptibility testing of clinical Pseudomonas aeruginosa isolates].

  Acuner IC, Bayramoğlu G, Birinci A, Cekiç Cihan C, Bek Y, Durupınar B. Acuner IC, et al. Mikrobiyol Bul. 2011 Jul;45(3):411-21. Mikrobiyol Bul. 2011. PMID: 21935774 Turkish.
• Evaluation of Vitek2 and BD Phoenix in antimicrobial susceptibility testing of Acinetobacter baumannii and Pseudomonas aeruginosa.

  Jekarl DW, Han SB, Kim YJ, Shin SH, Park KG, Park JJ, Han K, Park YJ. Jekarl DW, et al. Diagn Microbiol Infect Dis. 2010 Aug;67(4):384-6. doi: 10.1016/j.diagmicrobio.2010.02.024. Diagn Microbiol Infect Dis. 2010. PMID: 20638609
• In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.

  Solak S, Willke A, Ergönül O, Tekeli E. Solak S, et al. Int J Antimicrob Agents. 2005 Feb;25(2):181-2. doi: 10.1016/j.ijantimicag.2004.11.005. Int J Antimicrob Agents. 2005. PMID: 15664492 No abstract available.
• Antibacterial susceptibility testing in the clinical laboratory.

  Joyce M, Woods CW. Joyce M, et al. Infect Dis Clin North Am. 2004 Sep;18(3):401-34, vii. doi: 10.1016/j.idc.2004.04.001. Infect Dis Clin North Am. 2004. PMID: 15308270 Review.